Centre for Vascular Research, University of New South Wales, 3rd floor, Lowy Cancer Research Centre, Sydney, NSW 2052, Australia.
J Mol Med (Berl). 2011 Apr;89(4):343-61. doi: 10.1007/s00109-010-0709-z. Epub 2010 Dec 18.
Conditions resulting in retinal angiogenesis and edema (exudative age-related macular degeneration, diabetic retinopathy, retinal vein occlusion and retinopathy of prematurity) are major causes of visual impairment, with significant impact on quality of life. There has been increasing clinical usage of anti-vascular endothelial growth factor (anti-VEGF) agents to stop retinal angiogenesis and resolve intraretinal fluid arising from these conditions. However, anti-VEGFs have not been completely successful in curing these conditions, and a range of emerging treatments aimed at supplementing or competing with anti-VEGF agents are being developed. We will discuss the proposed merits these emerging agents bring to the treatment arsenal and how they compare with anti-VEGFs with regards to therapeutic activity, potency, specificity and safety. This review will also highlight recent pre-clinical research findings and suggest where future research might be directed.
导致视网膜血管生成和水肿的疾病（渗出性年龄相关性黄斑变性、糖尿病性视网膜病变、视网膜静脉阻塞和早产儿视网膜病变）是视力损害的主要原因，对生活质量有重大影响。抗血管内皮生长因子（anti-VEGF）药物的临床应用日益增多，这些药物可以阻止视网膜血管生成，并解决这些疾病引起的视网膜内液。然而，anti-VEGFs 并没有完全成功地治愈这些疾病，并且正在开发一系列旨在补充或与 anti-VEGF 药物竞争的新兴治疗方法。我们将讨论这些新兴药物对治疗武器库带来的益处，以及它们在治疗活性、效力、特异性和安全性方面与 anti-VEGFs 的比较。本综述还将强调最近的临床前研究结果，并提出未来研究的方向。
